Biomarin Pharmaceutical Ord Shs (BMRN)

$118.67 0.98 (0.82%)

18:49 EDT BMRN Stock Quote Delayed 30 Minutes

Volume:

Previous Close $118.67

Market Cap 20.97B

PE Ratio -141.27

EPS -0.84

Volume (Avg. Vol.) 754,300

Day's Range 117.81 - 120.75

52-Week Range 62.88 - 131.95

Dividend & Yield N/A (N/A)

BMRN Stock Predictions, Articles, and Biomarin Pharmaceutical Ord Shs News

From InvestorPlace
From the Web

5 Strong Buy Biotech Stocks for the Second Half

By Harriet Lefton, Writer, TipRanks Jun 19, 2019

We are now approaching the second half of 2019. And it may be time for a little portfolio rebalancing. Biotech stocks often move independently from the market, and these 5 are worth a look.

5 Biotech Stocks That Could Face M&A Next!

By Aaron Levitt, InvestorPlace Contributor Jan 10, 2019

Big biotech buyouts have already started happening. These five biotech stocks could be the next to go.

18 Stocks That Could Be Takeover Targets

By Vince Martin, InvestorPlace Contributor Jul 10, 2018

These takeover stocks all look like promising takeover targets at a time when M&A activity is likely to pick up.

3 Biotech Stocks Up in the Past Month on Industry Turnaround

By Zacks Investment Research Jun 15, 2018

We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after dec....

5 Biotech Stocks to Boost Your Portfolio’s Health This Year

By Zacks Investment Research May 31, 2018

Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio. Compare Brokers....

4 Biotech Stocks With Leaky Pipelines

By Regina Borsellino Apr 10, 2018

A strong pipeline can make or break biotech stocks, ensuring strong profits for years to come. These four biotech companies don't make the cut.

Compare Brokers

5 Biotech Stocks With Amazing Pipelines

By Regina Borsellino Mar 27, 2018

Biotech stocks are only as good as their pipeline. These five biotech companies are about to put out promising new drugs, with more products in the works.

Why BioMarin Pharmaceutical Inc. Stock Is Surging Today

By William White, InvestorPlace Writer Dec 11, 2017

BioMarin (BMRN) stock was on the rise today following positive news for its gene therapy efforts to treat severe hemophilia.

Earnings Growth Make BioMarin Pharmaceuticals (BMRN) a Sell

By Portfolio Grader Nov 6, 2017

Portfolio Grader currently ranks BioMarin Pharmaceuticals (NASDAQ:BMRN) a Sell. Using Louis Navellier's investing methodology, this analytical tool researches stocks by means of fundamental and quantitative analytical tools. BMRN has maintained this ranking for 4 months.

3 Big Stock Charts for Wednesday: Twilio Inc (TWLO), BioMarin Pharmaceutical Inc. (BMRN) and Mondelez International Inc (MDLZ)

By Johnson Research Group Aug 23, 2017

BioMarin Pharmaceutical (BMRN), Mondelez International (MDLZ) and Twilio (TWLO) are all teetering on the brink of bearish signals.

Wall Street’s 5 Hottest Biotech Stocks Right Now

By Harriet Lefton, Writer, TipRanks Jul 17, 2017

These five top biotech stocks have the seal of approval from the Street, with 'strong buy' analyst consensus ratings and big upside.

3 Pivotal Drug Trials to Watch for Explosive Potential

By Samuel Rae, InvestorPlace Contributor Jun 29, 2017

Here's a look at three biotech stocks that have at least one treatment prepped to enter pivotal clinical trials soon.

Compare Brokers

5 Great Biotech Stocks to Buy Now (CLLS, CELG, EXAS, EXEL, SNSS)

By Zacks Investment Research Feb 8, 2017

Biotechs have stabilized and offer the potential to deliver substantial returns. Here are 5 biotech stocks that fit our investment criteria

33 Biotechnology Stocks to Sell Now

By Portfolio Grader Aug 29, 2016

This week, the ratings of 33 Biotechnology stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

23 Biotechnology Stocks to Sell Now

By Portfolio Grader Aug 22, 2016

This week, the overall grades of 23 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").